You are viewing the site in preview mode

Skip to main content

Advertisement

Articles

Page 1 of 37

  1. Content type: Research article

    Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may arg...

    Authors: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen and Stijn L. W. Koolen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:192

    Published on:

  2. Content type: Research article

    Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell ac...

    Authors: David M. Richards, Viola Marschall, Katharina Billian-Frey, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Julian P. Sefrin, Matthias Schröder, Jaromir Sykora, Harald Fricke, Oliver Hill, Christian Gieffers and Meinolf Thiemann

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:191

    Published on:

  3. Content type: Research article

    Innate immune cells such as macrophages are abundantly present within malignant ascites, where they share the microenvironment with ovarian cancer stem cells (CSC).

    Authors: Shreya Raghavan, Pooja Mehta, Yuying Xie, Yu L. Lei and Geeta Mehta

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:190

    Published on:

  4. Content type: Research article

    Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy. As such, identifying strategies to bolster anti-t...

    Authors: A. J. Robert McGray, Ruea-Yea Huang, Sebastiano Battaglia, Cheryl Eppolito, Anthony Miliotto, Kyle B. Stephenson, Amit A. Lugade, Gill Webster, Brian D. Lichty, Mukund Seshadri, Danuta Kozbor and Kunle Odunsi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:189

    Published on:

  5. Content type: Research article

    Immunotherapy has shown remarkable clinical promise in the treatment of various types of cancers. However, clinical benefits derive from a highly inflammatory mechanism of action. This presents unique challeng...

    Authors: Matthew R. Schuelke, Phonphimon Wongthida, Jill Thompson, Timothy Kottke, Christopher B. Driscoll, Amanda L. Huff, Kevin G. Shim, Matt Coffey, Jose Pulido, Laura Evgin and Richard G. Vile

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:188

    Published on:

  6. Content type: Research article

    Micro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimenta...

    Authors: Martin Hart, Barbara Walch-Rückheim, Lena Krammes, Tim Kehl, Stefanie Rheinheimer, Tanja Tänzer, Birgit Glombitza, Martina Sester, Hans-Peter Lenhof, Andreas Keller and Eckart Meese

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:187

    Published on:

  7. Content type: Hypothesis

    Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In ...

    Authors: Cormac Cosgrove, Emilia R. Dellacecca, Joost H. van den Berg, John B. Haanen, Michael I. Nishimura, I. Caroline Le Poole and Hans E. N. Bergmans

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:186

    Published on:

  8. Content type: Research article

    Limitations to current therapies for treating non-Hodgkin B cell lymphoma include relapse, toxicity and high cost. Thus, there remains a need for novel therapies. Oncolytic viral (OV) therapy has become a prom...

    Authors: Minjun Yu, Iris Scherwitzl, Silvana Opp, Aristotelis Tsirigos and Daniel Meruelo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:185

    Published on:

  9. Content type: Position article and guidelines

    Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum,...

    Authors: Ezra E. W. Cohen, R. Bryan Bell, Carlo B. Bifulco, Barbara Burtness, Maura L. Gillison, Kevin J. Harrington, Quynh-Thu Le, Nancy Y. Lee, Rom Leidner, Rebecca L. Lewis, Lisa Licitra, Hisham Mehanna, Loren K. Mell, Adam Raben, Andrew G. Sikora, Ravindra Uppaluri…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:184

    Published on:

  10. Content type: Review

    Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. TMB can be quantitated by a number of...

    Authors: Laura Fancello, Sara Gandini, Pier Giuseppe Pelicci and Luca Mazzarella

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:183

    Published on:

  11. Content type: Case report

    In solid organ transplant (SOT) recipients, transplant rejection during immune checkpoint inhibitor (ICI) treatment for cancer is a clinical problem. Donor-derived cell-free DNA (dd-cfDNA) can be detected in b...

    Authors: Daan P. Hurkmans, Jeroen G. H. P. Verhoeven, Kitty de Leur, Karin Boer, Arjen Joosse, Carla C. Baan, Jan H. von der Thüsen, Ron H. N. van Schaik, Ron H. J. Mathijssen, Astrid A. M. van der Veldt and Dennis A. Hesselink

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:182

    Published on:

  12. Content type: Case report

    High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary...

    Authors: Valerie Glutsch, Franziska Grän, Judith Weber, Anja Gesierich, Matthias Goebeler and Bastian Schilling

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:181

    Published on:

  13. Content type: Research article

    Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the patients do not respond to these treatments and...

    Authors: Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Chung-Ting Han, Maria Kopp, Maximilian Frick, Bernhard Klumpp, Nicola Tietze, Teresa Amaral, Peter Martus, Tobias Sinnberg, Thomas Eigentler, Ulrike Keim, Claus Garbe…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:180

    Published on:

  14. Content type: Research article

    Immune cells play a key role in cancer progression and treatment. It is unclear whether the clinicopathologic characteristics and blood indexes of colorectal cancer (CRC) patients could predict immune cell con...

    Authors: Guifang Guo, Yixing Wang, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang and Liangping Xia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:179

    Published on:

  15. Content type: Research article

    CD4+ T cells are critical effectors of anti-tumor immunity, but how tumor cells influence CD4+ T cell effector function is not fully understood. Tumor cell-released autophagosomes (TRAPs) are being recognized as ...

    Authors: Yong-Qiang Chen, Peng-Cheng Li, Ning Pan, Rong Gao, Zhi-Fa Wen, Tian-Yu Zhang, Fang Huang, Fang-Yuan Wu, Xi-Long Ou, Jin-Ping Zhang, Xue-Jun Zhu, Hong-Ming Hu, Kang Chen, Yun-Lang Cai and Li-Xin Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:178

    Published on:

  16. Content type: Short report

    We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. D...

    Authors: Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride and Sandra Demaria

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:177

    Published on:

  17. Content type: Research article

    Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citr...

    Authors: Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet and Etienne Giroux Leprieur

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:176

    Published on:

  18. Content type: Short report

    Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell d...

    Authors: Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline and Hongtao Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:175

    Published on:

  19. Content type: Research article

    DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune res...

    Authors: Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat and Vincenzo Cerullo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:174

    Published on:

  20. Content type: Research article

    Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used mark...

    Authors: Menno Tamminga, Sanne de Wit, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Leon W. M. M. Terstappen and Harry J. M. Groen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:173

    Published on:

  21. Content type: Research article

    Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches t...

    Authors: Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:172

    Published on:

  22. Content type: Research article

    Traditional therapies fail to cure most glioblastoma patients and the 5-year survival rate is less than 10%, highlighting need for new therapeutic approaches. The natural killer group 2 member D ligands (NKG2D...

    Authors: Dong Yang, Bin Sun, Hongjiu Dai, Wenxuan Li, Lan Shi, Peixian Zhang, Shirong Li and Xudong Zhao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:171

    Published on:

  23. Content type: Short report

    Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor ...

    Authors: Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia and Evan J. Lipson

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:170

    Published on:

  24. Content type: Case report

    Compared to conventional chemotherapy, Immune checkpoint inhibitors (ICI) are known to have a distinct toxicity profile commonly identified as immune-related adverse events (irAEs). These irAEs that are believ...

    Authors: Abdul Rafeh Naqash, Ebenezer Appah, Li V. Yang, Mahvish Muzaffar, Mona A. Marie, Justin D. Mccallen, Shravanti Macherla, Darla Liles and Paul R. Walker

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:169

    Published on:

  25. Content type: Research article

    Natural killer (NK) cells are an emerging new tool for cancer immunotherapy. To develop NK cell therapeutics from peripheral blood mononuclear cells (PBMCs) of healthy donors, substantial expansion of primary ...

    Authors: Yeon Ho Choi, Eun Jin Lim, Se Wha Kim, Yong Wha Moon, Kyung Soon Park and Hee-Jung An

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:168

    Published on:

  26. Content type: Correction

    Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

    Authors: Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M. Coussens, Daniel D. De Carvalho, David G. DeNardo, Jérôme Galon, Howard L. Kaufman…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:167

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:131

  27. Content type: Hypothesis

    Primary adrenal failure (Addison’s disease) is a rare complication of immune checkpoint inhibitor (ICI) therapy. Untreated – and also sometimes under adequate hydrocortisone replacement therapy – the levels of...

    Authors: Igor Alexander Harsch

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:166

    Published on:

  28. Content type: Research article

    The risk of delayed autoimmunity occurring months or years after discontinuation of immunotherapy is frequently asserted in the literature. However, specific cases were rarely described until 2018, when a wave...

    Authors: Marcus A. Couey, R. Bryan Bell, Ashish A. Patel, Meghan C. Romba, Marka R. Crittenden, Brendan D. Curti, Walter J. Urba and Rom S. Leidner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:165

    Published on:

  29. Content type: Research article

    The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies off...

    Authors: Louise M. E. Müller, Matthew Holmes, Joanne L. Michael, Gina B. Scott, Emma J. West, Karen J. Scott, Christopher Parrish, Kathryn Hall, Sina Stäble, Victoria A. Jennings, Matthew Cullen, Stewart McConnell, Catherine Langton, Emma L. Tidswell, Darren Shafren, Adel Samson…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:164

    Published on:

  30. Content type: Research article

    Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipo...

    Authors: Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan and Craig L. Slingluff Jr

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:163

    Published on:

  31. Content type: Case report

    In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint i...

    Authors: Rayan Alsuwaigh, Joycelyn Lee, Gloria Chan, Cheng Ean Chee and Su Pin Choo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:162

    Published on:

  32. Content type: Research article

    Melanoma is a very aggressive skin tumor that can be cured when diagnosed and treated in its early stages. However, at the time of identification, the tumor is frequently in a metastatic stage. Intensive resea...

    Authors: Lise Pasquet, Elisabeth Bellard, Sophie Chabot, Bostjan Markelc, Marie-Pierre Rols, Justin Teissie and Muriel Golzio

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:161

    Published on:

  33. Content type: Research article

    Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. Clinica...

    Authors: Mathieu Grapin, Corentin Richard, Emeric Limagne, Romain Boidot, Véronique Morgand, Aurélie Bertaut, Valentin Derangere, Pierre-Antoine Laurent, Marion Thibaudin, Jean David Fumet, Gilles Crehange, François Ghiringhelli and Céline Mirjolet

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:160

    Published on:

  34. Content type: Commentary

    Recent phase 1–2 trials reported manageable safety profiles and promising antitumor activities of anti-PD-1 drugs (pembrolizumab, nivolumab, camrelizumab and JS001) with/without chemotherapy in recurrent/metas...

    Authors: Jia-Wei Lv, Jun-Yan Li, Lin-Na Luo, Zi-Xian Wang and Yu-Pei Chen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:159

    Published on:

  35. Content type: Correction

    Following publication of the original article [1], the authors reported an error in the Acknowledgments section. It should be read: ‘We are grateful to Mohsin Shah from the Department of Emergency Medicine at ...

    Authors: Noha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, Daniel H. Johnson, Van Anh Trinh, Chrystia M. Zobniw, Heather Lin, Michael K. Wong, Maen Abdelrahim, A. Osama Gaber, Maria E. Suarez-Almazor and Adi Diab

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:158

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2019 7:106

  36. Content type: Research article

    Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) in the tumor microenvironment i...

    Authors: Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, Wei Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou and Kebin Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:157

    Published on:

  37. Content type: Research article

    Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have t...

    Authors: Song Liu, Junko Matsuzaki, Lei Wei, Takemasa Tsuji, Sebastiano Battaglia, Qiang Hu, Eduardo Cortes, Laiping Wong, Li Yan, Mark Long, Anthony Miliotto, Nicholas W. Bateman, Shashikant B. Lele, Thinle Chodon, Richard C. Koya, Song Yao…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:156

    Published on:

  38. Content type: Short report

    Tumor-associated macrophages have been well-characterized in solid malignancies, including renal cell carcinoma and generally correlate with poor prognosis. However, the molecular mechanisms which govern intra...

    Authors: Jason B. Muhitch, Nicholas C. Hoffend, Gissou Azabdaftari, Austin Miller, Wiam Bshara, Carl D. Morrison, Thomas Schwaab and Scott I. Abrams

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:155

    Published on:

  39. Content type: Research article

    Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how...

    Authors: Qingnan Zhao, Jiemiao Hu, Abhisek Mitra, Jeffry Cutrera, Wendong Zhang, Zhongting Zhang, Jun Yan, Xueqing Xia, Kris Michael Mahadeo, John Andrew Livingston, Richard Gorlick and Shulin Li

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:154

    Published on:

  40. Content type: Short report

    PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients w...

    Authors: William Damsky, Lucia Jilaveanu, Noel Turner, Curtis Perry, Christopher Zito, Mary Tomayko, Jonathan Leventhal, Kevan Herold, Eric Meffre, Marcus Bosenberg and Harriet M. Kluger

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:153

    Published on:

  41. Content type: Research article

    T-cell mediated immunotherapy brought clinical success for many cancer patients. Nonetheless, downregulation of MHC class I antigen presentation, frequently occurring in solid cancers, limits the efficacy of t...

    Authors: Koen A. Marijt, Marjolein Sluijter, Laura Blijleven, Sofie H. Tolmeijer, Ferenc A. Scheeren, Sjoerd H. van der Burg and Thorbald van Hall

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:152

    Published on:

  42. Content type: Research article

    Binding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory signals that promote exhaustion of activated T cells. Blockade of the PD-1 pathway is widely used for cancer tre...

    Authors: Jesús Ogando, María Eugenia Sáez, Javier Santos, Cristina Nuevo-Tapioles, Marta Gut, Anna Esteve-Codina, Simon Heath, Antonio González-Pérez, José M. Cuezva, Rosa Ana Lacalle and Santos Mañes

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:151

    Published on:

  43. Content type: Research article

    While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial...

    Authors: Y. Maurice Morillon II, Zhen Su, Jeffrey Schlom and John W. Greiner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:150

    Published on:

  44. Content type: Research article

    Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for mark...

    Authors: Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts and Reno Debets

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:149

    Published on:

  45. Content type: Research article

    Molecular subtyping of urothelial cancer (UC) has significantly advanced the understanding of bladder tumor heterogeneity and development of prognostic and predictive biomarkers. Evolving evidence across cance...

    Authors: Thiago Vidotto, Sarah Nersesian, Charles Graham, D. Robert Siemens and Madhuri Koti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:148

    Published on:

  46. Content type: Research article

    Tumor-associated macrophages (TAMs) are the major component of tumor-infiltrating immune cells. Macrophages are broadly categorized as M1 or M2 types, and TAMs have been shown to express an M2-like phenotype. ...

    Authors: Chanju Lee, Hyunju Jeong, Younghyeon Bae, Kyungmoon Shin, Sinwoo Kang, Hwikyung Kim, Jayoung Oh and Hyunsu Bae

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:147

    Published on:

  47. Content type: Research article

    Pet dogs spontaneously develop lymphoma. An anthracycline-based multidrug chemotherapy regimen represents the treatment cornerstone; however, cure is rarely achieved. We have been treating dogs with B-cell lym...

    Authors: Laura Marconato, Luca Aresu, Damiano Stefanello, Stefano Comazzi, Valeria Martini, Roberta Ferrari, Fulvio Riondato, Nicole Rouquet, Patrick Frayssinet and Silvia Sabattini

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:146

    Published on:

  48. Content type: Short report

    Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...

    Authors: Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling and Howard L. Kaufman

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:145

    Published on:

  49. Content type: Case report

    Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. ...

    Authors: Joseph Vento, Aditi Mulgaonkar, Layton Woolford, Kien Nham, Alana Christie, Aditya Bagrodia, Alberto Diaz de Leon, Raquibul Hannan, Isaac Bowman, Renee M. McKay, Payal Kapur, Guiyang Hao, Xiankai Sun and James Brugarolas

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:144

    Published on:

  50. Content type: Case report

    PD-1/PD-L1 inhibitors are promising approaches for advanced Merkel cell carcinoma (MCC). Nevertheless, these inhibitors bear a high risk for induction of immune-related adverse events (irAEs), particularly fla...

    Authors: Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, Saskia Bolz, Selma Sirin, Martin Glas, Jürgen C. Becker, Selma Ugurel, Alexander Roesch, Dirk Schadendorf, Elisabeth Livingstone, Tim Hagenacker and Lisa Zimmer

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:141

    Published on:

Annual Journal Metrics

Advertisement